Cargando…

Tumor downstaging in muscle invasive bladder cancer with neoadjuvant systemic therapy—does it lead to prolonged survival?

Detalles Bibliográficos
Autores principales:	Tachibana, Isamu, Kaimakliotis, Hristos Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215006/ https://www.ncbi.nlm.nih.gov/pubmed/32420193 http://dx.doi.org/10.21037/tau.2019.12.28

Ejemplares similares

Editorial comment: the effect of neoadjuvant chemotherapy on tumour downstaging and outcomes in patients with muscle invasive bladder cancers
por: Ismaili, Nabil
Publicado: (2020)

Molecular downstaging: a new paradigm for neoadjuvant endocrine therapy
por: Ferraro, Emanuela, et al.
Publicado: (2020)

Downstaging of TURBT-Based Muscle-Invasive Bladder Cancer by Radical Cystectomy Predicts Better Survival
por: van Dijk, P. R., et al.
Publicado: (2011)

Downstaging and survival after Neoadjuvant chemotherapy for bladder cancer in Norway; a population-based study
por: Møller, Christina Tanem, et al.
Publicado: (2022)

Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction
por: Kamarajah, S. K., et al.
Publicado: (2020)

Will chemoradiation-based bladder-sparing therapy become a standard of care for muscle-invasive bladder cancer?
por: Koga, Fumitaka
Publicado: (2020)

Factors influencing downstaging after neoadjuvant long-course chemoradiotherapy in rectal carcinoma
por: Kohl, Valerie K. B., et al.
Publicado: (2022)

Surviving travel or travelling to survive: the association of travel distance with survival in muscle invasive bladder cancer
por: Kim, Albert H., et al.
Publicado: (2018)

Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer
por: Peyrottes, Arthur, et al.
Publicado: (2021)

Neoadjuvant cisplatin-based chemotherapy in “primary” and “secondary” muscle-invasive bladder cancer—is it a surrogate for molecular subtypes?
por: Szarvas, Tibor, et al.
Publicado: (2019)

Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story
por: Barosi, Giovanni, et al.
Publicado: (2022)

Advanced gastric cancer: CT radiomics prediction and early detection of downstaging with neoadjuvant chemotherapy
por: Xu, Qinmei, et al.
Publicado: (2021)

Functional and Clinicopathologic Outcomes Using a Modified Vescica Ileale Padovana Technique
por: Flack, Chandra K., et al.
Publicado: (2015)

Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer
por: Jayaratna, Isuru S., et al.
Publicado: (2015)

Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
por: Sherif, Amir, et al.
Publicado: (2018)

Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer
por: Carvalho, Filipe LF., et al.
Publicado: (2020)

Prognosis of rectal cancer patients improves with downstaging by intensified neoadjuvant radiochemotherapy - a matched pair analysis
por: Schiffmann, Leif, et al.
Publicado: (2013)

Prognostic implications of the extent of downstaging after neoadjuvant therapy for oesophageal adenocarcinoma and oesophageal squamous cell carcinoma
por: Kamarajah, Sivesh K, et al.
Publicado: (2023)

Lymphovascular space invasion and lack of downstaging after neoadjuvant chemotherapy are strong predictors of adverse outcome in young women with locally advanced breast cancer
por: Khwaja, Shariq S., et al.
Publicado: (2015)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
por: Elsayed, Dalia Hamouda, et al.
Publicado: (2023)

Age does not matter: the relevance of immediate instillation therapy with Mitomycin C in non-muscle invasive bladder cancer
por: Christoph, Frank, et al.
Publicado: (2018)

Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
por: Narayan, Vivek, et al.
Publicado: (2016)

Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer
por: McFerrin, Coleman, et al.
Publicado: (2020)

Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Miyagi, Hiroko, et al.
Publicado: (2022)

Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer
por: Razzaghdoust, Abolfazl, et al.
Publicado: (2021)

Downstaging of a Rectal Gastrointestinal Stromal Tumor by Neoadjuvant Imatinib Therapy Allowing for a Conservative Surgical Approach
por: dos Santos Fernandes, Gustavo, et al.
Publicado: (2009)

Neoadjuvant Tyrosine Kinase Downstaging of T2 Renal Cell Carcinoma in Solitary Kidney Before Robotic Partial Nephrectomy
por: Powers, Mary K., et al.
Publicado: (2015)

Rectal cancer patients with downstaging after neoadjuvant chemoradiotherapy and radical resection do not benefit from adjuvant chemotherapy
por: Zhang, Hang, et al.
Publicado: (2020)

Retrospective research of neoadjuvant therapy on tumor-downstaging, post-operative complications, and prognosis in locally advanced rectal cancer
por: Li, Wen-Chang, et al.
Publicado: (2021)

Does Radical Cystectomy Improve Overall Survival in Octogenarians with Muscle-Invasive Bladder Cancer?
por: Yoo, Sangjun, et al.
Publicado: (2011)

Editorial Comment: Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients
por: Korkes, Fernando
Publicado: (2021)

Editorial comment: bladder preservation as a treatment strategy in muscle-invasive bladder cancer
por: Ajib, Khaled, et al.
Publicado: (2018)

Predicting response to neoadjuvant chemotherapy in bladder cancer: controversies remain with genomic DNA sequencing
por: Seiler, Roland
Publicado: (2016)

Clinical benefit to regionalization of care for muscle invasive bladder cancer
por: Haque, Waqar, et al.
Publicado: (2018)

Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion
por: Eldefrawy, Ahmed, et al.
Publicado: (2012)

Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer
por: Marcq, Gautier, et al.
Publicado: (2019)

Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?
por: Renner, Alex, et al.
Publicado: (2021)

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
por: Chen, Hualin, et al.
Publicado: (2022)

Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Predictive molecular biomarkers for determining neoadjuvant chemosensitivity in muscle invasive bladder cancer
por: Murphy, Neal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n6167p6n09tu0lkqa9e1gm3cg5